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Nephrology is a subspecialty 
often associated with expensive 
and technologically advanced 
therapies. Furthermore, paed­
iatric nephrology services are 
limited as there are only a few registered 
paediatric nephrologists in South Africa 
(SA), almost all of whom practise in tertiary 
academic hospitals distributed unevenly across 
the country. The objective of this article is to 
provide information to general practitioners 
and paediatricians caring for children with 
chronic kidney disease (CKD). 
The Kidney Disease Improving Global 
Outcomes guideline proposes the following 
definition of CKD:
• Abnormalities of kidney structure 
or function that have been present 
>3 months, with implications for the 
health of the patient, and either of the 
following: 
• decreased glomerular filtration rate 
(GFR) <60 mL/min/1.73 m2, and/or 
• presence of markers of kidney damage. 
• Markers of kidney disease include any of 
the following: 
• proteinuria (urine dipstick ≥2+ or urine 
protein:creatinine ratio 5 × the upper 
limit of normal)
• urine sediment abnormalities
• electrolyte and other abnormalities 
caused by tubular disorders
• histological abnormalities
• structural abnormalities detected by 
imaging 
• history of renal transplantation.
The aforementioned definition does not apply 
to children <2 years of age in whom an 
appropriate age­adjusted GFR value should 
be used instead of GFR <60 mL/min/1.73 m2. 
Mature adult renal function is only achieved 
at 2 years of age. In infants ≤3 months old, a 
duration of >3 months does not apply. 
Causes of CKD in 
children 
Causes of CKD can be primary, i.e. no 
systemic disease present, or secondary, i.e. 
systemic disease affecting the kidney.
The most common causes of CKD in 
children are: 
• congenital abnormalities of the kidney and 
urogenital tract (CAKUT), e.g. obstructive 
uropathy and reflux nephropathy
• hypoplastic/dysplastic kidneys
• primary focal and segmental glomerulo­
sclerosis (nephrotic syndrome)
• haemolytic uraemic syndrome
• immune complex glomerulonephritis/
chronic glomerulonephritis
• hereditary nephropathies, e.g. polycystic 
kidney disease




In children the estimated GFR (eGFR) is 
calculated using the modified Schwartz 
formula: 
[40 × height (cm)] ÷ serum creatinine 
(µmol/L) (ml/min/1.73 m2).
Table 1 lists the GFR categories.
Proteinuria category 
A positive urine dipstick test for proteinuria 
should be confirmed with quantitative 
proteinuria measurement (measured as 
urine:protein:creatinine ratio (g/mmol) on 
a spot urine sample). Table 2 shows the 
proteinuria categories applicable to children.
Proteinuria is influenced by age, e.g. 
infants usually have a higher urinary loss 
of both glomerular and tubular protein, 
underlying pathology, and stage of CKD. 
Proteinuria eventually develops in all 
patients with CKD and is both a marker 
and a risk factor for the progression of this 
condition. 
Symptoms and signs of 
CKD
Acquired CKD is generally a silent disease, 
which may only become symptomatic in its 
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Table 1. GFR categories 
GFR category* GFR (mL/min/1.73 m2)
G1 ≥90
G2 60 ­ 89
G3a 45 ­ 59
G3b 30 ­ 44
G4 15 ­ 29
G5 <15
*Applicable to all children >2 years of age.
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more advanced stages. Symptoms are often 
nonspecific, e.g. infants usually present with 
feeding­related complaints. Poor growth 
is the single most common, and almost 
universal, feature in all children. 
In infants with CAKUT, the disease 
may be discovered by routine antenatal 
ultrasound scanning during pregnancy. In 
older children, the diagnosis may come as 
a complete surprise when a pathological 
condition is discovered co­incidentally.
Medical history 
This should start with the antenatal history 
and include the perinatal and infant 
periods and other preceding illnesses and 
investigations, and concentrate on current 
symptoms of all the major organ systems.
Of importance is the history of the antenatal 
period with regard to CAKUT in the fetus, 
including oligohydramnios, maternal disease 
(e.g. hypertension (HT), infections, diabetes 
mellitus), and drug exposure (e.g. non­
steroidal anti­inflammatory drugs (NSAIDs) 
and angiotensin­converting enzyme (ACE) 
inhibitors).
Routine antenatal ultrasound scanning 
in the maternal and fetal unit is the most 
important diagnostic tool to diagnose 
CAKUT before the infant becomes symp­
tomatic. Ideally, every woman should have 
at least one antenatal ultrasound scan 
during pregnancy, which is the practice in 
developed countries.
Kidney disease presents with nonspecific 
complaints, which contributes to a delay 
in making the diagnosis. Parents are often 
unable to recall the onset of symptoms 
because of the insidious nature of the disease. 
A family history of kidney disease or 
specific pathology in other systems associated 
with inherited kidney disease, such as 
deafness, ear and eye abnormalities and HT, 
may give an indication of the diagnosis. 
Examination
Clinical features associated with 
CKD
Longitudinal assessment of weight, length/
height and skull circum ference plotted on an 
appropriate growth chart, is most important 
when evaluating a child’s health. A complete 
physical examination should be done, 
including measurement of blood pressure 
(BP). HT in children is defined as systolic 
and/or diastolic BP ≥95th percentile for age, 
gender and height percentile. Ideally, one 
should use a BP percentile chart to interpret 
the BP level. Alternatively, a formula may be 
used, which provides a value corresponding 
to the 95th percentile BP for children of 
both sexes falling on the 50th percentile for 
height:
• systolic BP (95th percentile) – 1 ­ 17 years old: 
100+ (age in years × 2)
• diastolic BP (95th percentile) – 1 ­ 10 years old: 
60+ (age in years × 2)
• diastolic BP (95th percentile) – 11 ­ 17 years old: 
70+ (age in years).
Other presenting features include:
• dysmorphic features typical of a syndrome 
associated with CAKUT, e.g. Eagle­Barrett 
syndrome 
• tachypnoea mimicking acute ‘respiratory 
distress’ to compensate for metabolic 
acidosis
• chronic anaemia
• bone mineral disease, i.e. bone pain and 
skeletal deformities
• volume overload: oedema, HT, heart 
failure, pulmonary oedema
• uraemic symptoms and signs: nausea, 
vomiting, pruritus, brownish skin pig­
mentation, uraemic frost
• bleeding tendency (mucosa)
• convulsions due to HT, hyponatraemia, 
hypernatraemia, hypo calcaemia or uraemia.
Special investigations
• A urine dipstick test is an invaluable tool 
for the diagnosis of glomerular disease.
• A urine dipstick test does not detect tubular 
proteinuria, in which case urine amino 
acids or the β2­microglobulin:creatinine 
ratio should be measured.
• If proteinuria is present, the protein:creatinine 
ratio should be measured in an early­morning 
urine sample (normal <0.02 g/mmol).
• If a urine dipstick test reveals leucocytes 
and nitrites, a sterile sample of urine 
should be obtained for microscopy, 
culture and sensitivity.
• Twenty­four­hour urine or timed urine 
collection for creatinine clearance is 
impractical in children.
• Microscopy done on urine sediment 
provides information on the presence 
of dysmorphic red blood cells and 
red cell casts, which are diagnostic for 
glomerulonephritis.
• Serum urea, creatinine and electrolytes. 
Serum creatinine is necessary to calculate 
GFR. Serum urea is a poor tool to evaluate 
renal function, as it is influenced by hydration, 
nutritional status and protein intake. 
• Urine volume may be normal or increased 
(polyuria) (>4 mL/kg/hour), or decreased 
(oliguria) (<1.0 mL/kg/hour).
• Serum calcium, phosphate, alkaline 
phosphatase and plasma parathyroid 
hormone should be determined to assess 
bone mineral disease and secondary 
hyperparathyroidism.
• Renal ultrasound is necessary to 
demonstrate kidney size (small shrunken 
kidneys are characteristic of CKD) and 
exclude urinary tract obstruction. 
• There is no place for renal biopsy in 
patients with end­stage renal failure 
(ESRF).
Treatment
The principal renoprotective strategies 
with regard to modifiable risk factors for 
progression of CKD are the following: 
• Treat and control HT and fluid overload. 
HT and cardiovascular disease are the two 
most common causes of death in children 
with CKD.
• Treat proteinuria with an ACE inhibitor, 
even in the absence of HT. Minimise 
proteinuria, using maximum tolerable 
doses of ACE inhibitors.
• Control hyperphosphataemia and hyper­
parathyroidism and avoid hyper calcaemia. 
• Treat anaemia.
• Treat dyslipidaemia.
• Investigate and treat infections.
• Provide a balanced nutritious diet to allow 
for optimal growth.
Monitoring and follow-
up of children with CKD
Intervals between follow­up visits depend 
on the age of the child, staging of CKD and 
presence of complications. Children with 
stage 1 and 2 CKD are best followed up once 
every 6 months. Those with stage 3 and 4 
CKD need to be followed up every 2 ­ 3 
months.
Physical assessment at each visit should 
include:
• A complete physical examination. Monitor 
for end­organ damage of CKD. 
• Monitor anthropometry and assess 
nutritional status. 
• Monitor BP and cardiovascular system 
for volume overload, left ventricular 
hypertrophy/dilatation. 
Table 2. Proteinuria categories applicable to children
Category Protein:creatinine ratio (g/mmol) Terms
P1 <0.02 Normal 
P2 >0.02 ­ <0.2 Moderate increase, non­nephrotic range
P3 ≥0.2 Nephrotic range proteinuria
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• Monitor mineral and bone disorder, looking for muscle weakness, 
delayed closure of the anterior fontanelle, bowing or deformities 
of the long bones. 
• Assess neurodevelopment, especially in infants and children <5 years 
old.
• Fundoscopic examination must be done in all children with HT.
HT
The degree of HT correlates with severity of the underlying renal 
disease. 
• Use long­acting drugs, preferably once daily.
• Evening administration may be more beneficial.
• Control BP to <90th BP percentile.
• In children with proteinuria, lower­target BP is recommended: 
50 ­ 75th BP percentile as long as the child does not have symp­
toms of hypotension.
ACE inhibitors
• When proteinuria is present, an ACE inhibitor is the drug of choice 
for the treatment of HT. 
• Beneficial effects include: decreasing BP, decreasing proteinuria 
independent of its effect on systemic BP, and slowing down the 
progression of CKD.
• ACE inhibitors should be administered over a run­in period.
• Enalapril 0.1 mg/kg/dose should be administered once daily.
• The dose may be increased to 0.5 mg/kg/day as a single dose or 
two divided doses.
• ACE inhibitor treatment is also indicated in all children with persistent 
nephrotic range proteinuria and a GFR >30 mL/min/1.73 m2, even in 
absence of HT.
Monitoring treatment
• ACE inhibitors may cause hyperkalaemia, worsen metabolic 
acidosis or cause decline in renal function.
• It is obligatory to confirm tolerability and monitor serum 
potassium, bicarbonate, and renal function within 5 ­ 7 days after 
the start of treatment, and regularly thereafter as indicated by the 
level of renal function.
• If the serum creatinine increases by >25%, hydration status 
should be checked, diuretics discontinued and dose of ACE 
inhibitor halved.
• If renal function does not improve, or hyperkalaemia of >5.5 mmol/L 
persists, discontinue ACE inhibitors.
Calcium channel blockers (CCBs)
• CCBs do not have renoprotective effects other than controlling BP.
• They can increase proteinuria, and are best used in non­proteinuric 
patients or in combination with ACE inhibitor/angiotensin II 
receptor blocker treatment.
• Amlodipine 0.1 ­ 0.3 mg/kg/day as a single daily dose (maximum 
dose 10 mg/day).
β-blockers
•	 β­blockers decrease pulse rate, cardiac output, afterload and renin 
release.
• Administer atenolol 1 ­ 2 mg/kg as a single daily dose or in two 
divided doses per day.
Other antihypertensive drugs
If the BP remains uncontrolled, review treatment compliance. In most 
cases uncontrolled HT is caused by volume overload, a direct consequence 
of non­compliance relating to a low salt diet and drug treatment.
CKD – bone and mineral disorder 
CKD is associated with progressive phosphate retention, secondary 
hyperparathyroidism and development of bone mineral disease.
Management 
Management includes dietary restriction of phosphate, phosphate 
binders and activated vitamin D.
Phosphate binders
• These should be used in combination with dietary phosphate 
restriction.
• Most of dietary phosphate originates from protein­containing foods. 
• Restrict intake of dairy, grains and cereals, soft drinks, and food 
containing baking powder.
• Start phosphate binders early when the eGFR <70 mL/min/1.73 m2 
or serum phosphate >1.8 mmol/L.
• Maintain parathyroid levels within the normal range.
Types of phosphate binders
These include:
• calcium carbonate, calcium acetate and sevelamer
• calcium carbonate (Titralac) 1 ­ 4 tablets three times daily with meals
• calcium acetate and sevelamer (Renagel) are more expensive and 
not commonly used in children.
Hydroxylated vitamin D (1α-hydroxycholecalciferol or 1,25 
dihydroxycholecalciferol) therapy
• CKD is associated with a decreased production of activated 
vitamin D.
• Activated vitamin D should be given to all children with CKD with 
hypocalcaemia (serum calcium <2.2 mmol/L).
• If the serum phosphate is >2.5 mmol/L, hyperphosphataemia should 
be treated first to decrease serum phosphate to <1.8 mmol/L to 
prevent calcification of vascular and soft tissues.
• Start with α­calcidiol 0.25 µg/dose initially twice weekly.
• Increase the dose as necessary to maintain serum calcium in the 
upper normal range.
• Doses as high as 0.5 µg twice daily may be required.
Anaemia
Anaemia is defined as a haemoglobin (Hb) level of <11 g/dL in children 
6 months ­ 5 years, <11.5 g/dL in those 5 ­ 12 years and <12 g/dL in 
those 12 ­ 15 years.
Investigations 
• Complete blood count, including Hb, red cell indices, white cell 
count, differential count and platelet count.
• Absolute reticulocyte count.
• Serum ferritin level. 
• Serum transferrin saturation.
• Serum B12 level.
• Serum folate level. 
Management 
• Maintain optimal nutrition. 
• Exclude other factors that may contribute to anaemia, e.g. 
infections.
• Current available investigations are unreliable for the monitoring 
of iron status. Ferritin is an acute­phase reactant that may be 
elevated in malnutrition and systemic inflammation. The target 
serum ferritin level in the absence of inflammation is >100 ng/mL 
or 100 µg/L, and the target transferrin saturation (TSAT) is >20%.
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• If iron deficiency is present, treat with an oral iron supplement 
6 mg/kg elemental iron/day administered before eating or taking 
phosphate binders.
• Intravenous iron may be more practical for patients on 
haemodialysis.
• All children with CKD who are on erythropoietin­stimulating 
agents (ESA) should be treated with iron (oral or parenteral) to 
maintain TSAT >20% and a ferritin level >100 ng/mL.
• Consider treatment with ESA when anaemia is persistent despite 
correction of iron, folate and vitamin B2 deficiencies.
• BP must be controlled before starting ESA treatment.
• Start with 100  U/kg/week subcutaneously in two divided 
doses.
• Measure Hb, reticulocyte count and ferritin every 4 weeks.
• If the Hb increases <1 g/dL/month, exclude occult infection, blood 
loss or vitamin B12 or folate deficiency.
• If no cause is found, increase the ESA dose by 25 U/kg/week.
• Continue monitoring the Hb level every 4 weeks and adapt the dose.
• The maximum ESA dose is 300 U/kg/week.
• The target Hb is 10 ­ 12 g/dL.
• Once the target Hb level of 12 g/dL has been reached, continue 
with this dose.
• If the Hb increases >12 g/dL, discontinue erythropoietin for one 
week, and continue with 25 U/kg less per week.
Dyslipidaemia
Dyslipidaemia is an independent risk factor for cardiovascular 
disease and progression of CKD.
Management 
• Prevent malnutrition.
• Treat anaemia, correct metabolic acidosis and manage hyper­
parathyroidism.
• Lifestyle modification does not have impressive effects in children 
with dyslipidaemia.
• Consider treatment with a statin (hydroxymethylglutaryl 
co­enzyme A reductase inhibitor) in children >8 years of age with 
persistent total cholesterol levels >7 mmol/L.
• Administer simvastatin 10 mg at night (maximum dose 40 mg at 
night).
• Investigate for rhabdomyolysis if the child complains of muscle 
cramps.
Fluid and electrolyte balance
Sodium
• Infants with salt­losing CKD (obstructive uropathy and renal 
hypodysplasia) require NaCl supplementation. A starting dose of 
NaCl is 1 ­ 2 mmol/kg/day in divided doses. The dose is guided by 
serum sodium and chloride levels.
• Salt intake is restricted in patients with oedema, volume overload 
and HT.
• No salt should be added to food during preparation. Avoid salt­
preserved foods.
Water intake is not restricted and should be taken as desired.
Potassium
• Hyperkalaemia often occurs in association with catabolism and 
metabolic acidosis.
• Limit potassium intake if serum potassium >5.5 mmol/L.
• Restrict potassium­rich foods (fruit juices, fresh fruits and 
vegetables).
• Soak vegetables for 24 hours before cooking or decant water twice 
during cooking.
• Discontinue drugs that can cause hyperkalaemia (e.g. ACE inhibitors, 
β­blockers, spironolactone).
• If serum potassium remains >5.5 mmol/L, treat with sodium 
polystyrene sulphonate (Kexelate) 1 g/kg/dose dissolved in dex­
trose water administered orally once or twice daily.
Acid-base status
• Chronic metabolic acidosis causes anorexia and is associated with 
protein wasting.
• Correction of acidosis improves growth, prevents bone 
demineralisation and helps to manage hyperkalaemia.
• Treat with NaHCO3­  – starting dose 2 mmol/kg/day in 2 ­ 3 divided doses.
• Maintain serum HCO3­  between 18 and 24 mmol/L.
Nutrition and diet
• Protein restriction has no beneficial effects on the progression of 
CKD in children.
• It is associated with poor growth and the development of 
malnutrition.
• Children with CKD need a high­calorie and normal protein diet 
for optimal growth.
• Nasogastric tube feeds/gastrostomy feeds should be given if 
indicated.
Vitamins and minerals
• Multivitamin 5 mL daily, including vitamins B1, B6, B12 and C.
• Folic acid 2.5 mg daily.
Immunisation
• All children must complete routine immunisations according to 
the Expanded Programme of Immunisation schedule.
• Pneumovax (23 strain) 0.5 mL intramuscularly is given to children 
>2 years.
• Varicella zoster virus vaccine, 2 000  pfu/0.5 mL subcutaneously, 
reconstituted to 3 mL; two doses given with a 6­week dose interval.
• Check immunity against hepatitis B. In the absence of immunity, 
vaccinate as for any non­immune individual. 
• Hepatitis B vaccine 1 mL (3 µg) intramuscular injection, three 
doses at monthly intervals. 
• If the antibody level is considered non­protective or insufficient, 
give two booster doses one month apart.
Final recommendation 
Once a child reaches stage 3 CKD, referral to a paediatric 
nephrologist is necessary to discuss and/or start planning the 
potential future need of renal replacement therapy with the parents.
